SIGN UP
LOG IN
Quanterix Reaffirms Strategic Benefits Of Akoya Biosciences Acquisition, Targeting $1B Revenue Growth
Benzinga·03/03/2025 11:03:01
Listen to the news
- Expanded Addressable Market. The addition of Akoya'scutting-edge spatial biology capabilities will unlock a high-growth $5 billion serviceable addressable market across neurology, immunology and oncology, with an additional $10 billion market opportunity in Alzheimer's Disease diagnostics. By combining Quanterix's leading position in ultrasensitive detection of proteins in blood and Akoya's leading position in biomarker detection in tissue, Quanterix will be uniquely positioned to speed up development of new liquid biopsy tests, a market which it believes will surpass that of all other diagnostic tests combined.
- Synergy Generation: With extensive diligence and deep familiarity with Akoya's platform, Quanterix has clear line of sight to capture approximately $40 million in annual run-rate cost synergies by the end of 2026, $20 million of which is expected to be realized within the first year following close.
- Enhanced Scale and Profitability: With expected positive free cash flow in 2026 and continued strong double-digit organic revenue growth, Quanterix expects the transaction will allow it to multiply its revenue to approximately $1 billion with EBIT margins of approximately 15% within five years following close.
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.